The Firm represented the underwriters, led by Citigroup Global Markets Inc., Barclays Capital Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Wells Fargo Securities, LLC, in connection with the public offering of $2.0 billion of debt securities of Bristol-Myers Squibb Company (“BMS”), consisting of $750,000,000 of 0.875% Notes due 2017, $750,000,000 of 2.000% Notes due 2022 and $500,000,000 of 3.250% Notes due 2042.
BMS will use the net proceeds from the offering, the issuance of commercial paper and cash on hand (i) to finance the proposed acquisition of Amylin Pharmaceuticals, Inc. (“Amylin”); (ii) to pay certain costs, fees and expenses associated with the acquisition of Amylin; and (iii) for general corporate purposes.
BMS and its subsidiaries are engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The common stock of BMS is listed on the New York Stock Exchange (trading symbol BMY).
The Simpson Thacher team for the transaction included Risë Norman, Will Golden, Bharat Kejriwal and Rodrigo Surcan dos Santos (Capital Markets), Adeeb Fadil (Environmental), David Rubinsky and Jennifer Pepin (Executive Compensation and Employee Benefits), Mindy Lok and Andre Gray (IP), Adam Wells (Tax) and Krista McManus (Real Estate).